Age-related differences in the distribution, biology and treatment response of non-Hodgkin's lymphoma (NHL) in adolescents remain to be elucidated. The current analyses present clinical parameters and outcomes of adolescents treated in pediatric NHL-BFM trials. Patients were stratified by histological subtype: lymphoblastic lymphoma (LBL); mature B-NHL, including Burkitt's lymphoma/ leukemia (BL/B-AL), diffuse B-cell lymphoma (DLBCL-CB) and mediastinal B-cell lymphoma (PMLBL); and anaplastic large cell lymphoma (ALCL). Between October 1986 and December 2007, 2915 patients were registered, including 378 (13%) adolescents (15-18 years) with BL/B-AL (n ¼ 101), ALCL (n ¼ 74), DLBCL-CB (n ¼ 55), T-LBL (n ¼ 45), PMLBL (n ¼ 24), pB-LBL (n ¼ 13) and rare or not-specified NHL subtypes (n ¼ 66). The 5-year eventfree survival (EFS) was 79 ± 2% for adolescents compared with 85 ± 1% for patients aged o15 years (P ¼ 0.014). EFS was 83 ± 7% for adolescents with T-LBL, 82 ± 4% with BL/B-AL, 85 ± 5% with DLBCL-CB, 57 ± 10% with PMLBL and 70 ± 6% with ALCL. According to sex, the 5-year EFS in females versus males, respectively, was 70±5 versus 83±2% overall (P ¼ 0.004), 57±17 versus 92±6% (P ¼ 0.0036) for T-LBL patients and 71±9 versus 97 ± 3% (P ¼ 0.0067) for DLBCL-CB patients. Adolescents with NHL treated according to pediatric NHL-BFM protocols had an EFS of 79 ± 2%, which is marginally inferior to that of children. In adolescents with T-LBL and DLBCL-CB, female sex was associated with a worse prognosis.
Introduction
There are considerable differences between children and adults regarding the incidence, biology, treatment and outcome of non-Hodgkin's lymphoma (NHL). Adolescent patients form a separate group that falls between these categories. Although recent reports pay increasing attention to these patients, the impact of an adolescent age on the characteristics and outcome of NHL remains to be determined. [1] [2] [3] [4] Recently, adolescent NHL patients were treated following either a pediatric or adult protocol, and the criteria for the allocation of adolescents to pediatric or internal medicine departments vary within countries and between study groups.
Several retrospective analyses of the adolescent and young adult age groups with newly diagnosed acute lymphoblastic leukemia (ALL) treated according to either pediatric or adult protocols showed a statistically significantly superior outcome for patients treated with pediatric regimens. [5] [6] [7] [8] [9] In the United States, a retrospective study showed a clearly inferior outcome for adolescents when treated according to an adult regimen. These results inspired the investigators to plan a prospective study for adolescent and young adults with ALL using the more successful pediatric approach. 10 Similar analyses of adolescent NHL patients, that is, comparisons of treatment and outcomes between pediatric and adult protocols, are lacking. Furthermore, the lessons learned in adolescents with ALL cannot simply be transferred to NHL, as NHL in general is characterized by a complex heterogeneity of biology and treatment, which can also vary between different age groups. 3, 11 Prior to interdisciplinary discussions to improve therapy, the clinical and biological characteristics of NHL in adolescents need to be determined.
To allow further elucidation of NHL specifically in adolescent-aged (15-18 years) patients, the current analyses present the clinical characteristics and outcomes of 378 adolescents treated according to NHL-BFM protocols for childhood NHL. The analyses focused specifically on the adolescent age group and comprise an extended population compared with earlier reports from the NHL-BFM group. 11 
Materials and methods
The eligibility criteria for the clinical trials leading up to this retrospective study were: newly diagnosed NHL; age up to 18 years; no severe immunodeficiency, HIV infection or AIDS; no previous organ transplantation, malignancy, chemotherapy or radiotherapy or other pre-existing disease prohibiting chemotherapy as per the protocol; and informed consent from the patients' parents or guardians. 12 including a physical examination, peripheral blood and bone marrow (BM) smears, cerebrospinal fluid analyses, serum lactate dehydrogenase (LDH) levels and adequate imaging techniques. Initial central nervous system (CNS) disease was diagnosed in case of lymphoma cells in the cerebrospinal fluid (in patients with lymphoblastic lymphoma (LBL) X5 cells/ml cerebrospinal fluid were also required) and/or cerebral infiltrates on cranial computed tomography or magnetic resonance imaging and/or cranial nerve palsy not caused by an extradural mass. Patients with LBL and X25% BM blasts were diagnosed as having ALL and enrolled in ALL trials.
Diagnosis and staging

Therapy
Patients were stratified into three therapy groups as follows: group 1 included LBL including precursor T-and B-cell LBL (T-LBL and pB-LBL); group 2 included mature B-cell NHL including Burkitt's lymphoma/leukemia (BL/B-AL), diffuse large B-cell lymphoma of centroblastic subtype (DLBCL-CB), primary mediastinal B-cell lymphoma (PMLBL) and other mature aggressive B-NHL not further classified; and group 3 included anaplastic large cell lymphoma (ALCL). Because of constant diagnostic criteria over time and the clear predominance of centroblastic lymphoma (CB) in the group with DLBCL, the analysis of DLBCL was focused on the CB group. 13, 14 Patients belonging to group 1 received an ALL-type regimen consisting of an 8-drug induction (corticosteroid, vincristin, daunorubicin, asparaginase, cyclophosphamide, cytarabine, 6-mercaptopurine and intrathecal methotrexate) therapy and a consolidation (6-mercaptopurine, high-dose methotrexate, intrathecal methotrexate) and re-intensification (dexamethasone, vincristin, doxorubicin, asparaginase, cyclophosphamide, cytarabine, thioguanine and intrathecal methotrexate) therapy, which was followed by maintenance therapy (6-mercaptopurine and oral methotrexate) for a total therapy duration of 24 months. [15] [16] [17] Patients belonging to groups 2 or 3 received pulse-type therapy consisting of 5-day courses based upon dexamethasone, cyclophosphamide, ifosphamide, methotrexate, cytarabine, doxorubicine, etoposide and intrathecal therapy. 15, [18] [19] [20] [21] The number of courses was stratified mainly according to disease dissemination and tumor mass. For each study protocol, approval was obtained from the Institutional Review Board of the principal investigator (AR).
Statistical analysis
Survival probabilities were calculated using the Kaplan-Meier method with differences compared by log-rank test. 22, 23 Eventfree survival (EFS) was calculated from the date of initial diagnosis to the first event (death from any cause, progression/ relapse or second malignancy) or to the last follow-up visit. Overall survival (OS) was calculated from the date of diagnosis to the date of death from any cause. OS after relapse was calculated from the date of relapse to the date of death from any cause. Differences in the distribution of individual parameters among patient subsets were analyzed using w 2 test or Fisher's exact test for categorized variables, and the Mann-Whitney U-test for continuous variables. The Cox proportional hazards model was used for multivariate analyses. Statistical analyses were performed using the SAS program (SAS-PC, version 6.1, SAS Institute Inc., Cary, NC, USA). Follow-up observations extended through June 2009 (median 6.3 years).
Results
From October 1986 to December 2007, a total of 2915 patients treated with one of the protocols were registered in the NHL-BFM study center after providing informed consent. Of these 2915 NHL patients, 378 patients (13%) were adolescents (15-18 years of age) at diagnosis. Concerning the distribution of histological NHL subtypes in these adolescents, those with BL/B-AL were the largest subgroup (101 patients, 27%) followed by ALCL (74 patients, 20%), DLBCL-CB (55 patients, 15%), T-LBL (45 patients, 12%), PMLBL (24 patients, 6%), pB-LBL (13 patients, 3%), and other rare or not further specified NHL subtypes (66 patients, 17%). The distribution of histological subtypes within the series of adolescent NHL patients differed from the corresponding patients in the pediatric NHL series, including 2537 cases with BL/B-AL (49%), T-LBL (16%), ALCL (11%), DLBCL-CB (7%), pB-LBL (5%), PMLBL (1%), and other rare or not further specified NHL subtypes (11%; Po0.001; Figure 1 ).
Clinical characteristics
The adolescent group comprised 119 female and 259 male patients; 35% of patients presented with an elevated LDH level (X500 U/L) at diagnosis; 74% of adolescent NHL patients were diagnosed with advanced-staged disease (stage III or IV) according to the St Jude staging system; 12 and 14% of patients had BM involvement and 7% had CNS involvement at diagnosis. In all, 37% reported B symptoms at diagnosis and 31% had a poor performance status at diagnosis ( Table 1 ). The comparative analysis of patients' characteristics in pediatric and adolescent NHL patients showed a higher proportion of female patients in the adolescent age group, less frequent BM involvement, a higher frequency of B symptoms and a trend toward less frequent poor performance status in adolescents at diagnosis. Adolescents did not differ statistically from children regarding the frequency of elevated LDH levels (X500 and X1000 U/l), advanced-staged disease (4II) or CNS involvement (Table 1) .
Treatment stratification and outcome
Within the three therapy groups for LBL, mature B-NHL and ALCL, treatment intensity was stratified into risk groups Adolescents with NHL in pediatric NHL-BFM trials B Burkhardt et al according to the presence or absence of specific prognostic parameters. For patients enrolled in the subsequent trials NHL-BFM-90 and -95, which used similar stratification criteria, there was no difference in the distribution of the respective risk groups in all three therapy groups between pediatric and adolescent patients (Supplementary Table 1 ). Outcome analyses for the adolescent patients with a median follow-up of 4.4 years (range 0.1-19.7 years) showed a 5-year EFS of 79 ± 2% and an OS of 86 ± 2% ( Supplementary  Figures 1 and 2 ).
The outcome of adolescent NHL patients was inferior to that of the corresponding pediatric population, with 5-year EFS of 79 ± 2% for adolescents versus 85 ± 1% for children (P ¼ 0.014) and OS of 86±2 versus 90±1%, respectively (P ¼ 0.027). The comparison of events showed similar rates of deaths because of initial complications, treatment-related mortality and secondary malignancies in children and adolescents, but a comparatively higher rate of relapse in adolescents (Supplementary Table 2) .
Concerning the treatment period as a possible outcome factor, a trend toward better EFS in recent years (2002) (2003) (2004) (2005) (2006) (2007) , with EFS of 84 versus 81% in earlier years) is observed, but the difference was not statistically significant. This difference in EFS according to treatment period is even smaller in adolescents (81 versus 79%).
Impact of gender on adolescent NHL patients
Within the adolescent age group, there were statistically significant differences in clinical characteristics when comparing the 259 male and 119 female patients. Female adolescents were diagnosed more frequently with advanced stages (4stage II) and less frequently with CNS involvement ( Table 1 ). The 5-year EFS was 83 ± 2% for males compared with 70 ± 5% for females (P ¼ 0.0057) (Figure 2 ).
Characteristics and outcome of adolescent patients according to histological NHL subtypes
The 5-year EFS and 5-year OS differed according to histological subtypes and were 83±7 and 90±5%, respectively, in T-LBL, 85 ± 10 and 85 ± 10%, respectively, in pB-LBL, 82 ± 4 and 83±4%, respectively, in BL/B-AL, 85±5 and 90±4%, respectively, in DLBCL-CB, 57 ± 10 and 73 ± 9%, respectively, in PMLBL, 70±6 and 87±4%, respectively, in ALCL and 83±5 and 89±4%, respectively, for rare and not further classified NHL.
Lymphoblastic T-cell lymphoma
The T-LBL patient characteristics between children and adolescents were not statistically significantly different with respect to sex, LDH level, BM and/or CNS involvement, stage of disease, performance status or B symptoms (Table 2) . In outcome analyses, the 5-year EFS was similar in the pediatric (82 ± 2%) and adolescent T-LBL (83 ± 7%, P ¼ 0.41). However, the 5-year EFS within the adolescent group was significantly inferior for female T-LBL patients at 57 ± 17% compared with 92 ± 6% for adolescent male patients (P ¼ 0.0036), whereas clinical characteristics were similar in adolescent male and female patients (data not shown). In pediatric T-LBL patients (o15 years), the difference in EFS according to sex was absent, with 5-year EFS of 80±4% for females versus 83±2% for males (P ¼ 0.40, Table 3 ).
Burkitt's lymphoma and leukemia
The patient characteristics of adolescent BL/B-AL patients were not significantly different from pediatric BL/B-AL patients except for B symptoms, which were more frequent in adolescents (26 versus 38%, P ¼ 0.02; Table 2 ). The 5-year EFS tended to be superior in children compared with adolescent BL/B-AL patients (88 ± 1 versus 82±4%, P ¼ 0.063), mostly because of a higher rate of relapse in adolescents (data not shown). Within the adolescent BL/B-AL patients, outcome differed according to sex with a 5-year EFS of 84 ± 4% for males versus 69 ± 13% for females, but the difference did not reach statistical significance (P ¼ 0.21, Table 3 ).
Diffuse large B-cell lymphoma
The frequency of elevated LDH serum levels at diagnosis was significantly higher in adolescents compared with pediatric Table 1 Clinical characteristics of pediatric and adolescent NHL patients, and within the adolescent age group, according to sex Adolescents with NHL in pediatric NHL-BFM trials B Burkhardt et al patients (LDH X500 U/l in 25 versus 10% of patients, P ¼ 0.01; and LDH X1000 U/l in 9 versus 1% of patients, P ¼ 0.003; Table 2 ). In addition, initial BM involvement tended to occur more frequently in adolescents than in pediatric DLBCL-CB patients (4 versus 0%, P ¼ 0.05). The 5-year EFS of the 55 adolescent patients with DLBCL-CB was 85±5% compared with 96 ± 2% for the 187 pediatric DLBCL-CB patients (P ¼ 0.0019). Outcome analyses according to age group and sex showed no difference in EFS between male and female patients within the pediatric series, with a 5-year EFS of 97±2% for boys and 93 ± 3% for girls (P ¼ 0.24). However, within the adolescent age group, there was a significant difference in outcome according to sex with a 5-year EFS of 97 ± 3% for male and 71 ± 9% for female adolescent DLBCL-CB patients (P ¼ 0.0067, Table 3 ). Elevated LDH serum levels X500 and X1000 U/l were more frequent in adolescent females (11/24 and 5/24) compared with adolescent males (2/31 and 0/31). Advanced-staged disease (III/IV) (19/24 in females versus 4/31 in males) and B symptoms (10/24 in females versus 4/31 in males) were also significantly more frequent in adolescent girls with DLBCL-CB than in boys. In a multivariate analyses taking into account advanced stages III/IV, LDH X500 U/l and female sex, all three factors remained statistically significant, poor prognostic parameters (Table 4) .
Primary mediastinal large B-cell lymphoma
The comparison of clinical characteristics between pediatric (n ¼ 27) and adolescent (n ¼ 24) PMLBL patients showed B symptoms at diagnosis as the only statistically significant difference (26 versus 65%, P ¼ 0.015), whereas elevated LDH, advanced stage of disease, BM or CNS involvement and performance status at diagnosis were comparable in both groups (Table 2) . Within pediatric PMLBL patients, sex was split almost equally (48% female), whereas in adolescent PMLBL, females comprised two-thirds of the patient population (67%, P ¼ 0.26).
The 5-year EFS was 70 ± 9% for pediatric and 57 ± 10% for adolescent PMLBL patients (P ¼ 0.41).
Anaplastic large-cell lymphoma
Clinical characteristics were not statistically different between pediatric and adolescent ALCL patients except for a trend toward a higher frequency of advanced-stage disease in adolescents compared with pediatric ALCL patients (80 versus 68%, P ¼ 0.06). Outcomes for adolescents compared with children with ALCL showed no differences between the two age groups (70 ± 3 versus 70 ± 6%, Table 2 ) and, within the adolescent age group, there was no significant difference according to sex (Table 3) . Data on the immunohistochemical For the other histological NHL subtypes, the number of patients was too small to allow for detailed subgroup analyses.
Discussion
To our knowledge, these analyses of the clinical characteristics and outcomes of adolescent NHL patients diagnosed during a 21-year period and treated uniformly according to subsequent NHL-BFM protocols is the largest series studied to date. The aim of the study was to analyze the clinical characteristics and outcome of adolescent NHL patients treated according to pediatric protocols. In addition, the results obtained in adolescents were compared with the results of pediatric NHL patients enrolled during the same time period. In general, 495% of newly diagnosed pediatric NHL patients (o15 years of age) in Germany are registered in the NHL-BFM study center, which is documented by regular data exchanges between the German Children's Cancer Registry and the NHL-BFM study center. 24 However, until 2008, the upper age limit of newly diagnosed patients registered in the German Children's Cancer Registry was 14 years, and the adult registers just recently became mandatory. The rate of adolescent NHL patients (15) (16) (17) (18) years) treated at adult internal medicine departments in Germany is not accounted for by cancer registries, and therefore cannot currently be estimated. Consequently, the NHL-BFM data from pediatric patients are shown to be unbiased and population based, whereas the proportion of adolescent NHL patients treated according to adult protocols or outside of clinical trials cannot be determined.
The current analyses present data from 378 adolescent NHL patients treated according to pediatric NHL-BFM protocols. The study showed the 5-year EFS as 79 ± 2% and 5-year OS as 86±2% for adolescents. Compared with the corresponding population of 2537 pediatric NHL patients, the adolescent population included significantly more female patients, experienced B symptoms more often and had less often a poor performance status at the time of diagnosis. Interestingly, BM involvement was less frequent in adolescents than in the pediatric population. Concerning the distribution of histological subtypes, BL/B-AL, LBL, DLBCL and ALCL primarily represented the lymphoma subtypes diagnosed in the pediatric and adolescent age groups. However, the relative distribution of histological subtypes differed, with adolescents having Burkitt's lymphoma less frequently but having DLBCL-CB, ALCL and PMLBL more frequently. The Surveillance Epidemiology and End Results registry (SEER registry) data indicated that DLBCL was the most frequent subtype in adolescents and young adults in the United States. 3 The population reported in this study are not entirely homologous with the SEER population, as the SEER adolescent and young adult age group data included patients aged 15-39 years, which explains the higher prevalence of DLBCL in that registry. In the current analyses, indolent NHL subtypes were diagnosed very rarely and only in individual cases. Analogous observations were reported from the SEER registry with a relative increase in indolent lymphoma, particularly follicular lymphoma, beginning in the 20-to 24-year-old group. 3 Further analyses of our data on outcomes in adolescents showed a significant difference in EFS according to sex, with male adolescents having a higher EFS of 83±2% compared with 70 ± 5% in female adolescents (P ¼ 0.0057). Female adolescents presented more frequently with advanced-staged disease but less frequently with CNS involvement, whereas increased LDH level and BM involvement were equally frequent in both females and males. This sex-specific difference in outcomes for adolescent NHL patients was reproducible in some histological NHL subtypes, particularly in T-LBL and DLBCL-CB. For both subtypes, treatment results for male adolescents were similar to those of pediatric patients, whereas EFS in female adolescents with T-LBL was 57 ± 17 and 71 ± 9% in females with DLBCL-CB. A similar trend was seen in BL/B-AL, with an EFS of 69 ± 13% in female adolescents; however, this did not reach statistical significance because of the limited number of patients.
Presently, no clinical prognostic parameter has been established for T-LBL in pediatric trials. Adolescent age was reported to be of no prognostic relevance in some studies, [25] [26] [27] but the CCG502 trial, which included 281 eligible LBL patients, reported an increased relative risk of treatment failure of 2.7 for the 38 patients 414 years of age compared with 156 patients o10 years of age at diagnosis (P ¼ 0.0082). 28 Clinical trials in adult patients with LBL tend to achieve inferior results, as shown in Supplementary Table 3 . Hoelzer et al. 29 reported on 45 adult patients with T-LBL (age range 15-61 years) treated according to protocols designed for adult ALL. The 7-year OS was 51% (s.e. ± 10%). Survival according to age was 55% for 12 patients aged 15-20 years, 46% for 29 patients aged 21-50 years and 75% for 4 patients aged 450 years (P40.5). In all these trials, sex was not a statistically significant prognostic parameter. However, none of the publications provided data on the prognostic impact of adolescent age in combination with female sex. In parallel, molecular examinations of T-LBL cases showed differences between pediatric and adult T-LBL biology, reporting that immature phenotypes associated with poor prognosis predominantly occur in adult but not pediatric cases. 30 All in all, it remains difficult to draw decisive conclusions concerning the impact of age and sex on T-LBL patients. Pooled analyses, including several trials using similar treatment regimens accompanied by molecular characterizations, are required to assess the risks for adolescent T-LBL patients, particularly in females.
Adolescent age or age 410 years, respectively, has been reported to be associated with inferior outcomes in pediatric trials in patients with mature B-NHL, mainly Burkitt's lymphoma and DLBCL. 19, [31] [32] [33] Data on the additional impact of sex within the adolescent age group are lacking. Recently presented molecular data on somatic mutations in the variable region of rearranged immunoglobulin genes of 54 molecular Burkitt's lymphoma indicated two gene rearrangements occurring almost exclusively in pediatric patients o14 years of age, providing evidence for an antigen-driven selection, which might differ between pediatric and adult Burkitt's lymphoma cases. 34 The relevance of these preliminary data on the treatment and outcome of adolescent Burkitt's lymphoma patients must be further validated. In DLBCL, gene-expression profiling of adult cases identified two reproducible and robust DLBCL subtypes called germinal center cell-like (GC) or activated B-cell-like (ABC), which correlate with outcomes in adult DLBCL patients. 35, 36 The gene-expression profiling-based subdivision of DLBCL into GC and ABC subsets correlated with immunohistochemistry. 37 Based on this methodology, it could be shown that 83% of pediatric DLBCL cases present as a GC-like subtype, compared with only 45% of adult DLBCL patients, 13 a finding further confirmed by the pediatric FAB/LMB96 results that identified largely the GC subtype in the pediatric patient population. 38 Gene expression profiling of pediatric DLBCL was performed with nine specimens, of which four (44%) were GCB, 3 (33%) were ABC and 2 (22%) were type 3.
39 GC or ABC subtypes were not associated with age or sex in either study. However, the studies did not report the immunophenotypic association and prognostic relevance of adolescent age in combination with female gender. The comparison of the current data from adolescents with the treatment results achieved in adults with B-NHL or DLBCL revealed a significant impact of age on outcome (Supplementary Table 4) , which is also reflected in the international prognostic factor index including age below and above 60 years as an prognostic parameter. 40 Within the age groups, treatment results improved after the addition of rituximab to CHOP (cyclophosphamide, hydroxydaunorubicine, vincristin, predniso(lo)n) chemotherapy. 41, 42 PMLBL represents a distinct clinicopathologic subtype of mature B-NHL, 43 which was reported to occur predominantly in young women. 3 In the BFM series, 27 of a total of 51 PMLBL patients (56%) were aged o15 years, indicating that the diagnosis of PMLBL is not restricted to only adolescents or young adult patients. The clinical characteristics of pediatric and adolescent PMLBL are comparable to those reported in adults. [44] [45] [46] [47] [48] The current analyses identified a similar outcome for pediatric and adolescent PMLBL patients with NHL-BFM treatment (5-year EFS 70±9 and 57±10%, respectively; P ¼ 0.41), both of which are inferior to the results obtained in adult PMLBL patients who have up to 100% progression-freesurvival using dose-adjusted EPOCH with rituximab. 49 Interestingly, parallel to the excellent results in 35 PMLBL patients, Dunleavy et al. 49 reported on 12 patients with MGZL (mediastinal grey zone lymphoma) who fared worse with dose-adjusted EPOCH with rituximab and achieved only 30% progression-free-survival. The diagnosis of MGZL has not been established in pediatric mature B-NHL of the BFM series, and a careful review of the BFM patients is necessary to rule out that the current population represent a mixture of PMLBL and MGZL. This might be of particular relevance for the adolescent age group, as MGZL was primarily diagnosed in young adult patients.
Contrary to other NHL subtypes, adolescent age at diagnosis was of no prognostic relevance for ALCL patients treated according to NHL-BFM protocols. This observation is in line with the report of Brugieres et al., 50 who analyzed 82 pediatric ALCL patients with an overall 3-year EFS of 66%, in whom the EFS was 69% for the 38 patients aged X10 years. Age X10 years was of no prognostic relevance for 72 pediatric ALCL patients treated with a UKCCSG (United Kingdom Children's Cancer Study Group) chemotherapy regimen. 51 These data were added to the recently updated, pooled BFM-SFOP-UKCCSG analyses of prognostic parameters in ALCL, with 117 of 225 patients X10 years of age at diagnosis. 52 In univariate analysis, age X10 years was not associated with outcome (risk ratio 0.81 (0.50-1.3, P ¼ 0.41)). Concerning the ALK1 status, ALK1-negative ALCL is reported to occur more frequently with increasing age and is associated with inferior outcome. 53, 54 Within the current series, the frequency of ALK1-negative ALCL did not differ between pediatric and adolescent patients. The comparison of current outcome data in adolescents with published data on adult ALCL patients tends toward inferior survival in adults with ALCL, which might be, at least in part, related to the higher rates of ALKnegative ALCL in adult patients (Supplementary Table 5 ). [55] [56] [57] [58] [59] The current analyses showed that the 5-year-EFS of adolescent-aged NHL patients treated according to pediatric NHL-BFM protocols was 79 ± 2%, which is marginally inferior to that of younger children. Interestingly, within the adolescent-aged group itself, the outcome of male patients was similar to the outcome of pediatric NHL patients, whereas female adolescent patients achieved comparatively inferior EFS. This can only partly be explained by a sex-specific and uneven distribution of poor prognostic parameters; for example, in T-LBL patients, clinical characteristics were similar in female and male adolescents, whereas females with DLBCL-CB presented significantly more frequently with elevated LDH and disseminated disease. However, these subgroup analyses might be hampered by limited patient numbers. An obvious difference between male and female patients in the adolescent age group is the earlier onset of pubertal changes in females than in males, and differences in sex and growth hormone levels. The relevance of these sex-specific differences in developmental processes remains to be elucidated. During and after puberty, differences in body composition, that is, a higher fat mass in females, become apparent. These differences might influence distribution volumes, thereby influencing drug concentrations. In addition, as briefly mentioned above, there is increasing evidence for molecularly defined subsets of lymphoma within the main histological diagnoses, which suggest biological differences between pediatric and adult NHL; for example, the absence of immunogenetic immature T-LBL in children, the predominance of the GC subtype in pediatric DLBCL, the age-specific immunoglobulin rearrangements in Burkitt's lymphoma and the low frequency of ALK1-negative ALCL in children. However, the available data cannot explain the differences in outcome between female and male adolescents. Furthermore, the association between adolescent age, female sex and worse outcome in specific histological subtypes raises questions. These questions include: Are there biological differences in NHL in children compared with adolescents within the histological subgroups? Are these differences sex specific? Might there be patient subgroups within the adolescent and young adult patients resembling the biological features of adult NHL and vice versa? Which markers indicate molecular and biological lymphoma properties that are typically associated with specific prognostic lymphoma subsets? And furthermore, how can we optimize treatment and treatment stratification for patient subgroups as soon as they are identified? These questions need to be answered through interdisciplinary efforts.
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